NCT06225596 2026-04-15
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
BicycleTx Limited
Phase 2/3 Active not recruiting
Clinical Trials
9 trialsNCT07106762 2026-04-15
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT04628767 2026-04-14
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT07129993 2026-03-19
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Daiichi Sankyo
Phase 2/3 Recruiting
NCT06493552 2025-04-03
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Vasgene Therapeutics, Inc
Phase 2/3 Recruiting
NCT01438112 2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3 Terminated
NCT02240017 2019-08-09
VEFORA
Institut Claudius Regaud
Phase 2/3 Completed
NCT00389155 2015-12-07
First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy
Bristol-Myers Squibb
Phase 2/3 Completed
NCT00014274 2013-06-12
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2/3 Completed